Quinolones for Treatment of Human Brucellosis: Critical Review of the Evidence from Microbiological and Clinical Studies
Open Access
- 1 January 2006
- journal article
- review article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (1) , 22-33
- https://doi.org/10.1128/aac.50.1.22-33.2006
Abstract
Brucellosis is a zoonotic disease with worldwide distribution that is endemic in the Mediterranean region, the Middle East, Central Asia, and parts of Africa and Latin America. Worldwide, brucellosis remains a major cause of morbidity in humans and domesticated animals. In animals, bovineThis publication has 68 references indexed in Scilit:
- Brucellar SpondylitisJCR: Journal of Clinical Rheumatology, 2004
- Seroepidemiological and Microbiological Study of Brucellosis in KuwaitMedical Principles and Practice, 2004
- Chronic hepatosplenic abscesses in brucellosis. Clinico-therapeutic features and molecular diagnostic approachDiagnostic Microbiology and Infectious Disease, 2002
- Brucellar Spondylitis: Review of 35 Cases and Literature SurveyClinical Infectious Diseases, 1999
- Antibrucella Activity of Quinolone SparfloxacinJournal of Travel Medicine, 1995
- Susceptibility of Salmonella typhi and Brucella melitensis to the New Fluoroquinolone Rufloxacin (MF 934)Chemotherapy, 1993
- Use of ciprofloxacin in the treatment of brucellosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- Successful treatment ofBrucella melitensis endocarditis with pefloxacinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Antibacterial activity of lomefloxacin against Brucella melitensisPublished by Elsevier ,1990
- In vitro activity of ciprofloxacin againstBrucella melitensisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1984